A long term safety extension of Crenezumab in Mild to Moderate Alzheimer’s Disease (Genentech GN28525)
What is the Crenezumab in Mild to Moderate Alzheimer’s Study?
This is a Phase II multicenter study evaluating the long-term safety and tolerability of the drug crenezumab in patients with mild-to-moderate Alzheimer's disease.
What is the Purpose of the Crenezumab in Mild to Moderate Alzheimer’s Study?
Crenezumab is an antibody that is thought to inhibit the buildup of beta-amyloid in the brain. Eligibility The study is ongoing at the Memory and Aging Clinic at Butler Hospital, but is no longer enrolling subjects
For information on other current research studies at Butler Hospital please click here.